Document Classification

Section Type: METHODS

Text: In a phase II randomised study 165 patients with stage IIIB or IV NSCLC were assigned to receive docetaxel 40 mg/m (2) days 1 and 8 plus gemcitabine 1200 mg/m (2) days 1 and 8 every 21 days (arm A, N = 54) or docetaxel 50 mg/m (2) days 1 and 15 plus gemcitabine 1600 mg/m (2) days 1 and 15 every 28 days (arm B, N = 57) or gemcitabine 1200 mg/m (2) days 1 and 8 plus cisplatin 100mg/m (2) day 2 every 21 days for 3 cycles followed by docetaxel 75 mg/m (2) day 1 every 21 days for 3 cycles (arm C, N = 54).